Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration

Journal of Clinical Investigation

Volumn 126, Issue 5, 2016, Pages 1815-1833

  Xu, Wei ^a,b   Weissmiller, April M ^b   White, Joseph A ^c   Fang, Fang ^a,b   Wang, Xinyi ^a   Wu, Yiwen ^a   Pearn, Matthew L ^d,e   Zhao, Xiaobei ^b   Sawa, Mariko ^b   Chen, Shengdi ^a   Gunawardena, Shermali ^c   Ding, Jianqing ^a   Mobley, William C ^b   Wu, Chengbiao ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d University of California at San Diego   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; NERVE GROWTH FACTOR; RAB PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL FOREBRAIN; CELL DISRUPTION; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN SYNDROME; DROSOPHILA; EMBRYO; ENDOSOME; FEMALE; MALE; MOLECULAR MECHANICS; MOUSE; NERVE DEGENERATION; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RETROGRADE NERVE FIBER TRANSPORT; SIGNAL TRANSDUCTION; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; AXON; DISEASE MODEL; DROSOPHILA MELANOGASTER; ENDOCYTOSIS; FOREBRAIN; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AXONS; CHOLINERGIC NEURONS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; DROSOPHILA MELANOGASTER; ENDOCYTOSIS; MICE; MUTATION, MISSENSE; NERVE GROWTH FACTOR; PC12 CELLS; PROSENCEPHALON; RAB5 GTP-BINDING PROTEINS; RATS; SIGNAL TRANSDUCTION;

EID: 84978809499     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82409     Document Type: Article

References (120)

1. Selkoe DJ. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8(11):447-453.
2. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Ann N Y Acad Sci. 2000;924:17-25.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766.
4. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012;2(11):a011585.
5. Selkoe DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol. 2011;3(7):a004457.
6. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res. 2003;28(11):1705-1713.
7. Mori C, et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid. 2002;9(2):88-102.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
9. Cummings BJ, et al. Diffuse plaques contain C-terminal Aβ42 and not Aβ40: evidence from cats and dogs. Neurobiol Aging. 1996;17(4):653-659.
10. Citron M, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994;91(25):11993-11997.
11. Cork LC, et al. Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol. 1988;47(6):629-641.
12. Rasool CG, Svendsen CN, Selkoe DJ. Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease. Ann Neurol. 1986;20(4):482-488.
13. Coric V, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69(11):1430-1440.
14. Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(17):1661.
15. Doody RS, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341-350.
16. Donohue MC, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.
17. Ginsberg SD, et al. Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2010;22(2):631-639.
18. Grbovic OM, et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxylterminal fragment levels and Aβ production. J Biol Chem. 2003;278(33):31261-31268.
19. Laifenfeld D, et al. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J Neurosci. 2007;27(27):7141-7153.
20. Ikin AF, et al. Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5-containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway. J Biol Chem. 1996;271(50):31783-31786.
21. Buxbaum JD, Greengard P. Regulation of APP processing by intra- and intercellular signals. Ann N Y Acad Sci. 1996;777:327-331.
22. Bucci C, et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell. 1992;70(5):715-728.
23. Gorvel JP, et al. rab5 controls early endosome fusion in vitro. Cell. 1991;64(5):915-925.
24. Cataldo AM, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277-286.
25. Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8):a006361.
26. Cataldo AM, et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci. 2003;23(17):6788-6792.
27. Cattaneo A, Calissano P. Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis. Mol Neurobiol. 2012;46(3):588-604.
28. Salehi A, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51(1):29-42.
29. Ginsberg SD, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry. 2010;68(10):885-893.
30. Golde TE, et al. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255(5045):728-730.
31. Selkoe DJ, et al. β-Amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A. 1988;85(19):7341-7345.
32. Vetrivel KS, et al. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem. 2009;284(6):3793-3803.
33. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283(44):29615-29619.
34. Guo Q, et al. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012;22(1):78-89.
35. Kozlowski MR, et al. The neurotoxic carboxyterminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding. J Neurosci. 1992;12(5):1679-1687.
36. Jiang Y, et al. Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010;107(4):1630-1635.
37. Nosheny RL, et al. Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Neurobiol Dis. 2015;77:173-190.
38. Cooper JD, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A. 2001;98(18):10439-10444.
39. Albright CF, et al. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat. J Pharmacol Exp Ther. 2013;344(3):686-695.
40. Weissmiller AM, et al. A gamma-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One. 2015;10(2):e0118379.
41. Mitani Y, et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32(6):2037-2050.
42. Lauritzen I, et al. The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci. 2012;32(46):16243-16255a.
43. Bittner T, et al. γ-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009;29(33):10405-10409.
44. Tamayev R, et al. β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med. 2012;4(3):171-179.
45. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299-309.
46. Ginty DD, Segal RA. Retrograde neurotrophin signaling: Trk-ing along the axon. Curr Opin Neurobiol. 2002;12(3):268-274.
47. Glebova NO, Ginty DD. Growth and survival signals controlling sympathetic nervous system development. Annu Rev Neurosci. 2005;28:191-222.
48. Holtzman DM, et al. p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron. 1992;9(3):465-478.
49. Sofroniew MV, et al. Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science. 1990;247(4940):338-342.
50. Li Y, et al. Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci. 1995;15(4):2888-2905.
51. Holtzman DM, et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J Neurosci. 1995;15(2):1567-1576.
52. Perry EK. Nerve growth factor and the basal forebrain cholinergic system: a link in the etiopathology of neurodegenerative dementias? Alzheimer Dis Assoc Disord. 1990;4(1):1-13.
53. Reeves RH, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11(2):177-184.
54. Simonsen A, et al. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature. 1998;394(6692):494-498.
55. Stenmark H, et al. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 1994;13(6):1287-1296.
56. Zhang K, et al. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J Neurosci. 2013;33(17):7451-7462.
57. Rodrigues EM, Weissmiller AM, Goldstein LS. Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet. 2012;21(21):4587-4601.
58. Bryan-Sisneros AA, et al. Toxic effect of the β-amyloid precursor protein C-terminus fragment and Na+ /Ca2+ gradients. Neuroreport. 2000;11(15):3357-3360.
59. Hartell NA, Suh YH. Peptide fragments of β-amyloid precursor protein: effects on parallel fiber-Purkinje cell synaptic transmission in rat cerebellum. J Neurochem. 2000;74(3):1112-1121.
60. Oster-Granite ML, et al. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci. 1996;16(21):6732-6741.
61. Horiuchi H, et al. A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function. Cell. 1997;90(6):1149-1159.
62. Sanford JC, Pan Y, Wessling-Resnick M. Prenylation of Rab5 is dependent on guanine nucleotide binding. J Biol Chem. 1993;268(32):23773-23776.
63. Anderson JJ, Holtz G, Baskin PP, et al. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897.M Biochem Pharmacol. 2005;69(4):689-698.
64. Borgegard T, et al. First and second generation gamma-secretase modulators (GSMs) modulate Aβ production through different mechanisms. J Biol Chem. 2012;287(15):11810-11819.
65. Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry. 2013;52(19):3197-3216.
66. Grosveld GC. γ-Secretase inhibitors: Notch so bad. Nat Med. 2009;15(1):20-21.
67. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012;2(11):a011585.
68. Kopan R, Ilagan MXG. γ-Secretase: proteasome of the membrane? Nat Rev Mol Cell Biol. 2004;5(6):499-504.
69. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003;26:565-597.
70. Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem. 2012;120(suppl 1):89-98.
71. Liu J, et al. Nerve growth factor-mediated neurite outgrowth via regulation of Rab5. Mol Biol Cell. 2007;18(4):1375-1384.
72. Zhang Y, et al. Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation. J Neurosci. 2000;20(15):5671-5678.
73. Lee JP, et al. APP carboxyl-terminal fragment without or with abeta domain equally induces cytotoxicity in differentiated PC12 cells and cortical neurons. J Neurosci Res. 2000;60(4):565-570.
74. Sandhu FA, et al. Expression of the C terminus of the amyloid precursor protein alters growth factor responsiveness in stably transfected PC12 cells. Proc Natl Acad Sci U S A. 1996;93(5):2180-2185.
75. Zhang YW, et al. APP regulates NGF receptor trafficking and NGF-mediated neuronal differentiation and survival. PLoS One. 2013;8(11):e80571.
76. Gibbs RB. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol. 1998;151(2):289-302.
77. Granholm AC, Sanders LA, Crnic LS. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol. 2000;161(2):647-663.
78. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol. 1989;105(3):221-232.
79. Mufson EJ, et al. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003;26(4):233-242.
80. Mufson EJ, et al. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuroreport. 1996;8(1):25-29.
81. Mufson EJ, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002;443(2):136-153.
82. Muth K, et al. Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry. 2010;67(6):588-591.
83. Cabeza C, et al. Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor signaling in Niemann-Pick type C disease. Mol Neurodegener. 2012;7:11.
84. Williams B, Granholm AC, Sambamurti K. Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neurosci Lett. 2007;413(2):110-114.
85. Ginsberg SD, et al. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem. 2006;97(2):475-487.
86. Yuen EC, et al. Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev. 1996;18(5):362-368.
87. Das U, et al. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79(3):447-460.
88. Wu C, et al. The coming of age of axonal neurotrophin signaling endosomes. J Proteomics. 2009;72(1):46-55.
89. Cui B, et al. One at a time, live tracking of NGF axonal transport using quantum dots. Proc Natl Acad Sci U S A. 2007;104(34):13666-13671.
90. Sung K, et al. A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. J Neurosci Methods. 2011;200(2):121-128.
91. Zhao X, Zhou Y, Weissmiller AM, Pearn ML, Mobley WC, Wu C. Real-time imaging of axonal transport of quantum dot-labeled BDNF in primary neurons. J Vis Exp. 2014;(91):51899.
92. Suo D, et al. Coronin-1 is a neurotrophin endosomal effector that is required for developmental competition for survival. Nat Neurosci. 2014;17(1):36-45.
93. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951;116(2):321-361.
94. Fossgreen A, et al. Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. Proc Natl Acad Sci U S A. 1998;95(23):13703-13708.
95. Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001;32(3):389-401.
96. Fye S, et al. Visualization of larval segmental nerves in 3(rd) instar Drosophila larval preparations. J Vis Exp. 2010;(43):2128.
97. Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482(7384):216-220.
98. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217-1281.
99. Goldstein LS. Axonal transport and neurodegenerative disease: can we see the elephant? Prog Neurobiol. 2012;99(3):186-190.
100. Kanaan NM, et al. Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol. 2013;246:44-53.
101. Ye X, Tai W, Zhang D. The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging. 2012;33(6):1122.
102. Strom AL, et al. Retrograde axonal transport and motor neuron disease. J Neurochem. 2008;106(2):495-505.
103. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008;7(suppl 1):43-56.
104. El-Kadi AM, Soura V, Hafezparast M. Defective axonal transport in motor neuron disease. J Neurosci Res. 2007;85(12):2557-2566.
105. Baloh RH, et al. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci. 2007;27(2):422-430.
106. Stokin GB, Goldstein LS. Axonal transport and Alzheimer's disease. Annu Rev Biochem. 2006;75:607-627.
107. Charrin BC, Saudou F, Humbert S. Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease. Pathol Biol (Paris). 2005;53(4):189-192.
108. Kajiho H, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116(pt 20):4159-4168.
109. Kajiho H, et al. Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J Biol Chem. 2011;286(27):24364-24373.
110. Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458.
111. Chen Y, et al. APP-BP1 inhibits Aβ42 levels by interacting with Presenilin-1. Mol Neurodegener. 2007;2:3.
112. Chen Y, et al. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol. 2003;163(1):27-33.
113. Kamal A, et al. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron. 2000;28(2):449-459.
114. Inomata H, et al. A scaffold protein JIP-1b enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1. J Biol Chem. 2003;278(25):22946-22955.
115. Matrone C, et al. APP is phosphorylated by TrkA and regulates NGF/TrkA signaling. J Neurosci. 2011;31(33):11756-11761.
116. Mobley WC, et al. Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res. 1986;387(1):53-62.
117. Kaether C, et al. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic. 2006;7(4):408-415.
118. Fjorback AW, et al. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J Neurosci. 2012;32(4):1467-1480.
119. Wu C, Lai CF, Mobley WC. Nerve growth factor activates persistent Rap1 signaling in endosomes. J Neurosci. 2001;21(15):5406-5416.
120. Schnitzler AC, Lopez-Coviella I, Blusztajn JK. Purification and culture of nerve growth factor receptor (p75)-expressing basal forebrain cholinergic neurons. Nat Protoc. 2008;3(1):34-40.